COVID-19 Global Rheumatology Alliance
COVID-19 Global Rheumatology Alliance aim to collect, analyze and disseminate information about COVID-19 and rheumatology to patients, physicians and other relevant groups to improve the care of patients with rheumatic disease.
Description
More detailed information about this field from each metasource.
COVID-19 Global Rheumatology Alliance aim to collect, analyze and disseminate information about COVID-19 and rheumatology to patients, physicians and other relevant groups to improve the care of patients with rheumatic disease.
metasource: Fairsharing.orgversion: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Webpage:
https://rheum-covid.org/Webpage
More detailed information about this field from each metasource.
https://rheum-covid.org/
metasource: Fairsharing.orgversion: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Publications:
(6)
Publications
More detailed information about this field from each metasource.
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
PMID: 32471903
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
PMID: 32309814
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry
PMID: 33146001
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance
PMID: 32374851
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey
PMID: 32386125
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice
PMID: 32789449
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Publications
More detailed information about this field from each metasource.
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
PMID: 32471903
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
PMID: 32309814
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry
PMID: 33146001
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance
PMID: 32374851
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey
PMID: 32386125
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice
PMID: 32789449
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
PubMed citations: 485.
485 articles citing: Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry. PMID:35908834
Outcomes of COVID-19 in Inflammatory Rheumatic Diseases: A Retrospective Cohort Study. PMID:35903564
Systemic sclerosis in the time of COVID-19. PMID:35891634
Safety of Biologic-DMARDs in Rheumatic Musculoskeletal Disorders: A Population-Based Study over the First Two Waves of COVID-19 Outbreak. PMID:35891442
COVID-19 and liver diseases. PMID:35880136
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. PMID:35868584
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. PMID:35838348
Post-COVID 19 Interstitial Lung Disease: A New Treatment Challenge In Rheumatoid Arthritis Patients. PMID:35812304
Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes. PMID:35772080
Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal-A Multicenter, Nationwide Study. PMID:35770002
Evaluation of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Levels in Coronavirus Disease Breakthrough Infection During Immunosuppressive Therapy in a Patient with Connective Tissue Disease-Related Interstitial Lung Disease. PMID:35730997
Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. PMID:35729973
COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. PMID:35717727
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. PMID:35698725
A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases. PMID:35698182
Immune-Mediated Mechanisms of COVID-19 Neuropathology. PMID:35665037
Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy. PMID:35658585
Antimalarials - old drugs are new again. PMID:35645661
Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. PMID:35639259
Looking ahead: giant-cell arteritis in 10 years time. PMID:35634351
Critical Influenza and COVID-19-A Comparative Nationwide Case-Control Study. PMID:35620773
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients. PMID:35611100
BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective. PMID:35603097
COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. PMID:35598255
Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database. PMID:35588945
NSAID use and clinical outcomes in COVID-19 patients: a 38-center retrospective cohort study. PMID:35570298
Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality. PMID:35567479
Patients with idiopathic inflammatory myopathies suffer from worse self-reported PROMIS physical function after COVID-19 infection: an interview-based study from the MyoCite cohort. PMID:35562623
Fulminant onset COVID-19: predictors and outcome. PMID:35537807
Évaluation systématique de la réponse humorale contre le SARS-CoV-2 dans une cohorte française de 283 patients atteints d’un rhumatisme inflammatoire chronique. PMID:35530370
Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. PMID:35510167
Factors associated with hospitalizations for Covid-19 in patients with rheumatoid arthritis: data from the Reumacov Brazil registry. PMID:35505408
The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era. PMID:35503130
Different systemic rheumatic diseases as risk factors for COVID-19-related mortality. PMID:35499772
Clinical course and seroprevalence of COVID-19 in children with rheumatic diseases-cross-sectional study from a reference centre in Spain. PMID:35489011
Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis. PMID:35486976
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. PMID:35474640
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. PMID:35471956
SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study. PMID:35468758
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. PMID:35464809
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. PMID:35453593
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis. PMID:35441151
SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases. PMID:35434592
Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. PMID:35434582
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients. PMID:35427999
Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2? PMID:35410854
Factors associated to COVID-19 vaccine acceptance in Mexican patients with rheumatic diseases: A cross-sectional and multicenter study. PMID:35389817
COVID-19 therapeutics: Challenges and directions for the future. PMID:35385354
COVID-19 in patients with systemic lupus erythematosus: A systematic review. PMID:35382637
Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study. PMID:35382368
COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. PMID:35373130
Collateral Effects and Mortality of Kidney Transplant Recipients during the COVID-19 Pandemic. PMID:35373117
A glimpse into the future of systemic lupus erythematosus. PMID:35368371
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. PMID:35366735
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses. PMID:35365569
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. PMID:35360719
Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis. PMID:35352217
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. PMID:35338032
COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience. PMID:35335008
Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? PMID:35295608
Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. PMID:35286906
TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE. PMID:35282492
Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. PMID:35258593
Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. PMID:35252469
Eculizumab versus rituximab in generalised myasthenia gravis. PMID:35246490
Persistent post-discharge symptoms after COVID-19 in rheumatic and musculoskeletal diseases. PMID:35233480
Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. PMID:35231915
Targeting TNF-α for COVID-19: Recent Advanced and Controversies. PMID:35223745
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. PMID:35217850
Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. PMID:35214755
COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study. PMID:35214709
Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. PMID:35208467
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. PMID:35197452
Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. PMID:35177626
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. PMID:35172961
Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. PMID:35171364
An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. PMID:35167393
Overview of infections as an etiologic factor and complication in patients with vasculitides. PMID:35165771
The impact of the ongoing COVID-19 pandemic on the management of rheumatic disease: a national clinician-based survey. PMID:35165770
COVID-19 outcomes in persons with multiple sclerosis treated with rituximab. PMID:35158435
COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases. PMID:35155485
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy. PMID:35154159
Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID-19). PMID:35146925
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. PMID:35143648
Identification of Risk Factors for COVID-19 Hospitalization in Patients With Anti-Rheumatic Drugs: Results From a Multicenter Nested Case Control Study. PMID:35143039
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. PMID:35118829
Colchicine Against SARS-CoV-2 Infection: What is the Evidence? PMID:35107804
Innate immunity: the first line of defense against SARS-CoV-2. PMID:35105981
Therapeutic role of immunomodulators during the COVID-19 pandemic- a narrative review. PMID:35086413
The course of COVID-19 in patients with Behçet's disease. PMID:35079178
Blocking TNF signaling may save lives in COVID-19 infection. PMID:35076845
Diet and Hygiene in Modulating Autoimmunity During the Pandemic Era. PMID:35069526
Clinical course of Covid-19 in a cohort of patients with Behçet disease. PMID:35058051
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. PMID:35024352
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. PMID:35022159
Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. PMID:35006442
Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. PMID:35001198
Comorbidities as Risk Factors for Severe Disease in Hospitalized Elderly COVID-19 Patients by Different Age-Groups in Japan. PMID:34999588
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. PMID:34988877
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. PMID:34987092
COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers. PMID:34964022
Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. PMID:34959657
COVID-19 vaccination and breakthrough infections in patients with cancer. PMID:34958894
Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. PMID:34956607
COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges. PMID:34943795
Epidemiology of Pemphigus. PMID:34909708
[Erythrodermic psoriasis after COVID-19]. PMID:34905074
Updates in Psoriasis Management: Based on selected presentations from Maui Derm 2021 on January 25-29 in Grand Wailea, Maui, Hawaii. PMID:34904023
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. PMID:34901885
Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study. PMID:34890478
Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. PMID:34890121
Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. PMID:34887346
Systematic assessment of the humoral response against SARS-CoV-2 in a French cohort of 283 patients with rheumatic diseases. PMID:34883243
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. PMID:34880127
SARS-CoV-2 infection in children with rheumatic disease: Experience of a tertiary referral center. PMID:34870170
COVID-19 vaccine hesitancy among Mexican outpatients with rheumatic diseases. PMID:34856876
Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. PMID:34844296
Coronavirus disease 2019 in patients with Behcet's disease: a report of 59 cases in Iran. PMID:34842999
Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases. PMID:34838054
Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. PMID:34837569
Gout during the SARS-CoV-2 pandemic: increased flares, urate levels and functional improvement. PMID:34822044
Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders. PMID:34819488
IMPACT OF THE COVID PANDEMIC ON RHEUMATOLOGY PATIENTS IN NORTHERN IRELAND - A WEB BASED CROSS-SECTIONAL SURVEY OF PATIENT REPORTED OUTCOMES. PMID:34815603
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus. PMID:34806342
Pathogenesis and treatment of cytokine storm in COVID-19. PMID:34803441
Immunosuppression and COVID-19 infection in British Columbia: Protocol for a linkage study of population-based administrative and self-reported survey data. PMID:34797824
The paradox of immunosuppressants and COVID-19. PMID:34795039
Seronegative Erosive Arthritis Following SARS-CoV-2 Infection. PMID:34786669
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups. PMID:34781162
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. PMID:34779868
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. PMID:34778843
COVID-19 in systemic vasculitis and polymyalgia rheumatica: who is at risk of poor outcomes? PMID:34778842
Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan. PMID:34776348
[COVID-19 in Routine Rheumatologic Care]. PMID:34745375
An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy. PMID:34739462
Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. PMID:34716843
Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19. PMID:34710657
The impact of the COVID-19 pandemic on African American cancer survivors. PMID:34706056
COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. PMID:34696205
Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry. PMID:34688963
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. PMID:34670840
Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan. PMID:34669154
COVID-19 vaccination in patients with immunity-mediated kidney disease. PMID:34667284
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. PMID:34661663
Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. PMID:34659238
The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data. PMID:34648828
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study. PMID:34647194
Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. PMID:34622123
Association between previous rheumatoid arthritis and COVID-19 and its severity: a nationwide cohort study in South Korea. PMID:34620675
Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil. PMID:34620246
BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. PMID:34607791
Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases. PMID:34600751
Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. PMID:34599933
COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis. PMID:34596719
Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. PMID:34588749
Prior Immunosuppressive Therapy and Severe Illness Among Patients Diagnosed with SARS-CoV-2: a Community-Based Study. PMID:34581984
Perceptions and behaviours related to COVID-19 in patients with rheumatoid arthritis: a cross-sectional study. PMID:34581890
The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. PMID:34570263
Caution with the use of dexamethasone in patients with COVID-19 in its initial phases. PMID:34563488
Duration of infectious virus shedding in patients with severe coronavirus disease 2019 who required mechanical ventilation. PMID:34538728
Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. PMID:34538612
Characteristics of patients with immune-mediated inflammatory diseases hospitalized for SARS-CoV-2 infection. PMID:34538610
Impact of COVID-19 on Pediatric Immunocompromised Patients. PMID:34538297
Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study. PMID:34529226
Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis. PMID:34515976
Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark. PMID:34501290
Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. PMID:34498436
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. PMID:34491403
Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review. PMID:34490312
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. PMID:34485930
Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. PMID:34475732
The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. PMID:34475227
COVID-19 and the Use of Immunomodulatory Agents in Ophthalmology. PMID:34461710
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity. PMID:34454035
Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis. PMID:34452007
Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. PMID:34450504
A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK. PMID:34448203
Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review. PMID:34447687
Managing ANCA-associated vasculitis during the COVID-19 pandemic: results from an online survey. PMID:34427760
Poor Prognosis of COVID-19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross-Sectional Population Study Of 252 119 Patients. PMID:34423922
Factors Associated With Hospitalization and Death After COVID-19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data. PMID:34423917
Favorable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases. PMID:34414384
Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. PMID:34413630
No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study. PMID:34402949
COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study. PMID:34401883
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. PMID:34396154
Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. PMID:34368185
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. PMID:34363826
Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. PMID:34362053
Administration of COVID-19 vaccines in immunocompromised patients. PMID:34352567
A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster. PMID:34350721
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. PMID:34347939
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. PMID:34346564
NSAIDs and COVID-19: A Systematic Review and Meta-analysis. PMID:34339037
Treatment of COVID-19 in Patients With Sarcoidosis. PMID:34336892
The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. PMID:34335579
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far? PMID:34334801
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. PMID:34331051
Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study. PMID:34325226
Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. PMID:34321903
TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control Study. PMID:34316436
COVID-19 infections in sarcoidosis: a prospective single center study of 886 sarcoidosis patients. PMID:34316261
COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review. PMID:34311142
[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination]. PMID:34309739
COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic. PMID:34307589
Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. PMID:34303107
TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case-Control Study. PMID:34297311
Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease. PMID:34274035
SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. PMID:34273582
Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. PMID:34273260
Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). PMID:34269903
An aberrant inflammatory response in severe COVID-19. PMID:34265243
Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. PMID:34256812
Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt. PMID:34244818
Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. PMID:34241765
Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. PMID:34238376
The use of corticosteroids for COVID-19 infection. PMID:34235424
Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2. PMID:34229623
The 'cytokine storm': molecular mechanisms and therapeutic prospects. PMID:34217595
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia. PMID:34216998
Lupus Cohorts. PMID:34215374
COVID-19-related deaths among women of reproductive age in Brazil: The burden of postpartum. PMID:34213771
[German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic]. PMID:34196793
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. PMID:34189675
Factors associated with COVID-19 and its outcome in patients with rheumatoid arthritis. PMID:34189674
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. PMID:34179832
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. PMID:34179831
Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. PMID:34175865
The impact of the COVID-19 pandemic on the field of pediatric rheumatology. PMID:34175864
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. PMID:34171857
Psychological Effects of Lockdown Measures for the COVID-19 Outbreak in Patients with Systemic Lupus Erythematosus. PMID:34168460
Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease. PMID:34155573
Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases. PMID:34154620
Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan. PMID:34152562
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. PMID:34139567
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. PMID:34132811
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. PMID:34128356
Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. PMID:34126316
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. PMID:34117116
Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. PMID:34114951
Does methotrexate influence COVID-19 infection? Case series and mechanistic data. PMID:34112217
Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. PMID:34105883
Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. PMID:34095857
Defining COVID-19-associated hyperinflammatory syndrome in specific populations. PMID:34095856
Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). PMID:34095747
COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. PMID:34091704
COVID-19 in patients with gout on colchicine. PMID:34089357
Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. PMID:34075358
Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2. PMID:34075357
Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study. PMID:34060006
Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs. PMID:34052904
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. PMID:34049860
Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia. PMID:34049217
Prior immunosuppressive therapy is associated with mortality in COVID-19 patients: A retrospective study of 835 patients. PMID:34042195
Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. PMID:34033207
The impact of COVID-19 on familial Mediterranean fever: a nationwide study. PMID:34032894
Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. PMID:34031556
Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019. PMID:34014329
Impact of Smoking on Women During the Covid-19 Pandemic. PMID:33996840
Characteristics of Patients With Immune-Mediated Inflammatory Diseases Hospitalized for SARS-CoV-2 Infection. PMID:33985907
The impact of COVID-19 and healthcare system changes on the well-being of rheumatic patients. PMID:33976460
[Care of rheumatology patients during the lockdown in early 2020 : Telemedicine, delegation, patient satisfaction and vaccination behavior]. PMID:33974131
Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. PMID:33973389
COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database. PMID:33973280
The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding? PMID:33969248
The complex relationship between viruses and inflammatory bowel disease - review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic. PMID:33953797
Psoriasis, COVID-19 and shielding. PMID:33951179
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. PMID:33945214
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. PMID:33942031
Research and Management of Rare Diseases in the COVID-19 Pandemic Era: Challenges and Countermeasures. PMID:33937170
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. PMID:33936084
COVID-19 Among Patients With Inflammatory Rheumatic Diseases. PMID:33936073
Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. PMID:33934576
Lockdown effects on a patient receiving immunosuppression for unilateral HLA- B27 associated uveitis during COVID-19 pandemic. PMID:33913911
NSAID use and clinical outcomes in COVID-19 patients: A 38-center retrospective cohort study. PMID:33907758
COVID-19: The therapeutic landscape. PMID:33899041
Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia. PMID:33895100
COVID-19 and Disease-Modifying Anti-rheumatic Drugs. PMID:33893890
The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy. PMID:33892930
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. PMID:33884425
Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases. PMID:33875975
Machine Learning as a Precision-Medicine Approach to Prescribing COVID-19 Pharmacotherapy with Remdesivir or Corticosteroids. PMID:33865643
Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. PMID:33856739
Clinical characteristics and outcome of COVID-19 in patients with rheumatic diseases. PMID:33856543
Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel. PMID:33844415
Highlights from a year in a pandemic. PMID:33835146
Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. PMID:33831011
The role of antirheumatics in patients with COVID-19. PMID:33817665
Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. PMID:33812171
Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin? PMID:33789316
Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. PMID:33787086
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology. PMID:33783147
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. PMID:33762264
COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. PMID:33754931
Effect of COVID-19 confinement on the mental status of patients with systemic lupus erythematosus. PMID:33754127
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. PMID:33753416
Circulating Calprotectin as a Biomarker of COVID-19 Severity. PMID:33750254
Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID-19: A Binational, Registry-Based Cohort Study. PMID:33750043
The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study. PMID:33744354
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. PMID:33743151
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. PMID:33739362
COVID-19 and the clinical course of rheumatic manifestations. PMID:33733315
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. PMID:33728796
COVID-19 and shielding: experiences of UK patients with lupus and related diseases. PMID:33728396
COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. PMID:33725121
COVID-19 disease and the hyper-inflammatory response: Are we accusing the wrong suspect? PMID:33722434
[Caution with the use of dexamethasone in patients with COVID-19 in its initial phases]. PMID:33716310
Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. PMID:33713486
COVID-19 vaccination and antirheumatic therapy. PMID:33710296
Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. PMID:33706794
Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019. PMID:33706472
Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. PMID:33687528
SARS-CoV-2 vaccines in patients with SLE. PMID:33685998
Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19. PMID:33680426
Response. PMID:33678263
The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia. PMID:33677725
Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab. PMID:33674264
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. PMID:33655421
Changing COVID-19 outcomes in patients with rheumatic disease-are we really getting better at this? PMID:33655223
The racial/ethnic and sociocultural aspects of the pandemic in rheumatology. PMID:33648855
Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2? PMID:33644099
COVID-19 illness and autoimmune diseases: recent insights. PMID:33640999
Effect of COVID-19 confinement on the mental status of patients with systemic lupus erythematosus. PMID:33632510
Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. PMID:33628418
Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. PMID:33627440
Inflammatory arthritis in patients with COVID-19. PMID:33626415
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. PMID:33622688
Hospital admissions in inflammatory rheumatic diseases during the peak of COVID-19 pandemic: incidence and role of disease-modifying agents. PMID:33613703
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. PMID:33611869
Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. PMID:33609804
The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study. PMID:33604501
COVID-19 pneumonia in a patient with sarcoidosis: A case report. PMID:33598270
Risk and outcome of COVID-19 infection in sarcoidosis patients: results of a self-reporting questionnaire. PMID:33597796
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. PMID:33597206
Risk of COVID-19 hospital admission and COVID-19 mortality during the first COVID-19 wave with a special emphasis on ethnic minorities: an observational study of a single, deprived, multiethnic UK health economy. PMID:33597146
Bifurcated monocyte states are predictive of mortality in severe COVID-19. PMID:33594364
Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study. PMID:33592545
Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm. PMID:33580566
COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. PMID:33574819
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. PMID:33564756
The impact of COVID-19 on rheumatology patients in a large UK centre using an innovative data collection technique: prevalence and effect of social shielding. PMID:33559727
Impact of COVID-19 pandemic on management of autoimmune and inflammatory diseases in Morocco. PMID:33552358
COVID-19 pandemic management and the rheumatology patient. PMID:33536145
The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. PMID:33535498
Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. PMID:33527691
The protective effect of rheumatic disease agents in COVID-19. PMID:33526326
Managing patients using telerheumatology: Lessons from a pandemic. PMID:33526324
Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice. PMID:33521672
Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. PMID:33521671
Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. PMID:33521669
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. PMID:33521660
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? PMID:33521659
Divergent effects of acute versus chronic glucocorticoids in COVID-19. PMID:33521656
COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments. PMID:33519443
SARS-CoV-2 and Systemic Lupus Erythematosus. PMID:33511495
Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? PMID:33510644
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. PMID:33510041
SARS-CoV-2 infection in patients with autoimmune hepatitis. PMID:33508378
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. PMID:33504483
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. PMID:33502500
Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. PMID:33496334
COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study. PMID:33486110
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. PMID:33485957
Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? PMID:33483287
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. PMID:33480077
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. PMID:33479021
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. PMID:33478953
Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. PMID:33476581
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. PMID:33468418
[Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic]. PMID:33468416
Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? PMID:33455920
An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. PMID:33443778
COVID-19 vaccination in immunocompromised patients. PMID:33426632
The Impact of SARS-CoV-2 Outbreak on Primary Sjögren's Syndrome: An Italian Experience. PMID:33425954
Clinical course and outcomes of COVID-19 in rheumatic disease patients: a case cohort study with a diverse population. PMID:33420870
Effects of Bariatric Surgery on COVID-19: a Multicentric Study from a High Incidence Area. PMID:33417099
Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity. PMID:33414783
COVID-19 and mortality in rare rheumatic diseases, a warning bell? PMID:33410464
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. PMID:33408338
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. PMID:33394601
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study. PMID:33392516
Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review. PMID:33390974
Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab. PMID:33390490
Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. PMID:33388969
COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions. PMID:33387525
Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. PMID:33380344
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. PMID:33368145
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study. PMID:33359593
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. PMID:33352298
Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic. PMID:33344389
Rheumatic disease and COVID-19: epidemiology and outcomes. PMID:33339986
A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. PMID:33338707
Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. PMID:33325523
SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. PMID:33316070
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. PMID:33294881
Evolution of COVID-19 in patients with autoimmune rheumatic diseases. PMID:33289698
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. PMID:33277976
The risk for severe COVID 19 in patients with autoimmune and/or inflammatory diseases: First wave lessons. PMID:33277764
Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis. PMID:33269355
[Prospective monitoring of a university rheumatology outpatient clinic throughout the first wave of the COVID-19 pandemic : What lessons can be learned?]. PMID:33258019
Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. PMID:33257496
Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy. PMID:33231774
Association of TNF-α G-308 a Promoter Polymorphism with the Course and Outcome of COVID-19 Patients. PMID:33228423
Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions. PMID:33216852
Corticosteroid injections during the COVID-19 pandemic: experience from a UK centre. PMID:33215158
Clinical course of COVID-19 infection in inflammatory rheumatological patients: a monocentric Belgian experience. PMID:33210075
Rheumatoid Arthritis in the Era of COVID-19 Pandemic. PMID:33196002
COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. PMID:33193418
Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. PMID:33191284
Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. PMID:33181156
Tweets by People With Arthritis During the COVID-19 Pandemic: Content and Sentiment Analysis. PMID:33170802
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. PMID:33158877
Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. PMID:33154972
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. PMID:33146561
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. PMID:33146001
Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. PMID:33132221
Impact of COVID-19 pandemic on rheumatoid arthritis from a Multi-Centre patient-reported questionnaire survey: influence of gender, rural-urban gap and north-south gradient. PMID:33130920
COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse? PMID:33127600
COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. PMID:33123391
A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. PMID:33102507
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. PMID:33095083
Management of autoimmune disease during the COVID-19 pandemic. PMID:33093739
Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. PMID:33080571
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. PMID:33075408
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19? PMID:33073335
COVID-19 in Italian Sjögren's syndrome patients: a monocentric study. PMID:33070254
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey. PMID:33067320
Sex differences in clinical phenotype and transitions of care among individuals dying of COVID-19 in Italy. PMID:33066823
How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a global, cross-sectional, online survey. PMID:33065421
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. PMID:33051220
COVID, Biologics, and Psoriasis Therapy. PMID:33051006
The impact of COVID-19 pandemic on patients with ANCA associated vasculitis. PMID:33034038
Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis. PMID:33029203
The impact of COVID-19 on rheumatology practice across Africa. PMID:33020845
Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey. PMID:33011680
The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). PMID:33007104
The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. PMID:32996071
#Covid4Rheum: an analytical twitter study in the time of the COVID-19 pandemic. PMID:32995894
Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic. PMID:32972125
Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection. PMID:32965502
Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression. PMID:32953843
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. PMID:32945944
IBD in the COVID-19 era: the value of international collaboration. PMID:32941833
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. PMID:32931985
Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report. PMID:32930030
Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. PMID:32896705
Managing rheumatoid arthritis during COVID-19. PMID:32892311
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. PMID:32891785
Rheumatologists in the COVID-19 era: will there be a new role for the rheumatologist in the care of rheumatic patients? PMID:32889590
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. PMID:32878994
African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. PMID:32876786
Monocyte activation in systemic Covid-19 infection: Assay and rationale. PMID:32861199
Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. PMID:32860913
[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]. PMID:32845393
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. PMID:32838309
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. PMID:32838307
Pharmacotherapeutic considerations for systemic rheumatic diseases amid the COVID-19 pandemic: more questions than answers. PMID:32837197
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. PMID:32835190
A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. PMID:32797326
Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19. PMID:32796683
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. PMID:32796045
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. PMID:32789449
Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. PMID:32769150
Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al. PMID:32759257
[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]. PMID:32757030
Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. PMID:32735965
COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. PMID:32725762
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. PMID:32720259
Conducting research in a pandemic: The power of social media. PMID:32716838
Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. PMID:32715660
Putting patients at the centre of COVID-19 research. PMID:32710008
Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia? PMID:32709679
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. PMID:32705809
COVID-19 in Rheumatic Diseases: A Research Agenda. PMID:32705748
Risk to health from COVID-19 for anaesthetists and intensivists - a narrative review. PMID:32677708
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. PMID:32671831
Challenges of autoimmune rheumatic disease treatment during the COVID-19 pandemic: A review. PMID:32665090
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad. PMID:32654082
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. PMID:32654078
Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. PMID:32645207
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology. PMID:32640861
New data emerging on outcomes for patients with COVID-19 and rheumatic diseases. PMID:32620941
Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. PMID:32589798
Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. PMID:32584782
Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon et al. PMID:32475834 -
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
PubMed citations: 114.
114 articles citing: Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study. PMID:35909441
Risk of Severe SARS-CoV-2 Infection in Patients with Autoimmune Rheumatic Diseases in Qatar: A Cohort Matched Study. PMID:35813704
Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. PMID:35729973
Mortality related to COVID-19 in patients with rheumatic and musculoskeletal diseases, first wave of the outbreak: a single-center study. PMID:35510167
COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. PMID:35382249
Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry. PMID:35258593
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients. PMID:35243732
Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study. PMID:35197013
The impact of the ongoing COVID-19 pandemic on the management of rheumatic disease: a national clinician-based survey. PMID:35165770
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. PMID:34778843
Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases. PMID:34696255
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. PMID:34661663
Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. PMID:34622123
Challenges of Egyptian patients with systemic lupus erythematosus during the COVID-19 pandemic. PMID:34538954
Healthcare Resource Use in Patients with Immune-Mediated Conditions Treated with Targeted Immunomodulators During COVID-19 Pandemic: A Retrospective Claims Analysis. PMID:34515976
Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. PMID:34498436
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. PMID:34491403
Disability and COVID-19: ensuring no one is left behind. PMID:34416912
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. PMID:34316727
Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. PMID:34316725
Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. PMID:34312307
[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination]. PMID:34309739
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. PMID:34189675
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. PMID:34171857
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. PMID:34117116
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. PMID:34049860
Research and Management of Rare Diseases in the COVID-19 Pandemic Era: Challenges and Countermeasures. PMID:33937170
Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. PMID:33922777
Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV-2 infection increase the risk of vasculitis? PMID:33846189
COVID-19 pandemic management and the rheumatology patient. PMID:33536145
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. PMID:33533553
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. PMID:33521657
COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments. PMID:33519443
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. PMID:33504483
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. PMID:33502500
COVID-19 in Immunocompromised Hosts: What We Know So Far. PMID:33501974
Impact of COVID-19 on rheumatology practice in the UK-a pan-regional rheumatology survey. PMID:33495972
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. PMID:33485957
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. PMID:33468418
Risk Factors for COVID-19 and Rheumatic Disease Flare in a US Cohort of Latino Patients. PMID:33455077
COVID-19, rheumatic diseases and immune dysregulation-a perspective. PMID:33411143
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. PMID:33408338
COVID-19: What Do Rheumatologists Need to Know? PMID:33403528
The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature. PMID:33401171
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. PMID:33394601
A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. PMID:33338707
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. PMID:33268442
[Perspectives for rheumatological health services research at the German Rheumatism Research Center]. PMID:33258978
[Prospective monitoring of a university rheumatology outpatient clinic throughout the first wave of the COVID-19 pandemic : What lessons can be learned?]. PMID:33258019
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence? PMID:33196003
COVID-19 and systemic sclerosis: analysis of lifestyle changes during the SARS-CoV-2 pandemic in an Italian single-center cohort. PMID:33188620
COVID-19 and myositis - unique challenges for patients. PMID:33175137
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. PMID:33146561
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. PMID:33146001
Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. PMID:33132221
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. PMID:33051220
Severe Coronavirus Disease 2019 Infection in an Adolescent Patient After Hematopoietic Stem Cell Transplantation. PMID:33036110
The impact of COVID-19 pandemic on rheumatology practice: a cross-sectional multinational study. PMID:32996071
The contribution of the observational research design to COVID-19 research. PMID:32984848
Coronavirus disease 2019 (COVID-19) in patients with systemic autoimmune diseases or vasculitis: radiologic presentation. PMID:32981005
SARS-CoV-2 Infection and COVID-19 in 5 Patients in Ecuador After Prior Treatment with Hydroxychloroquine for Systemic Lupus Erythematosus. PMID:32978364
Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. PMID:32972804
Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic. PMID:32972125
Autoimmunity as the comet tail of COVID-19 pandemic. PMID:32953841
SARS-CoV-2 infection in an advanced rheumatoid arthritis patient. PMID:32945021
COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. PMID:32927376
Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. PMID:32896705
Patient-reported Disease Activity in an Axial Spondyloarthritis Cohort during the COVID-19 Pandemic. PMID:32893508
Rheumatologists in the COVID-19 era: will there be a new role for the rheumatologist in the care of rheumatic patients? PMID:32889590
African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. PMID:32876786
Social Media in the Times of COVID-19. PMID:32852927
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. PMID:32852623
Are Patients With Autoimmune Disease at Greater Risk of Developing Severe COVID-19? PMID:32849942
[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]. PMID:32845393
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. PMID:32838307
COVID-19 and systemic lupus erythematosus: a case series. PMID:32835249
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. PMID:32796045
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. PMID:32794113
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. PMID:32789449
[Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020]. PMID:32757030
What immunological and hormonal protective factors lower the risk of COVID-19 related deaths in pregnant women? PMID:32739645
Conducting research in a pandemic: The power of social media. PMID:32716838
Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists. PMID:32694358
Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment. PMID:32666137
Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic. PMID:32661928
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. PMID:32654078
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. PMID:32620062
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. PMID:32606046
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. PMID:32591970
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. PMID:32589189
Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. PMID:32571616
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. PMID:32569797
Covid-19 and autoimmunity. PMID:32535093
Cutaneous autoimmune diseases during COVID-19 pandemic. PMID:32534461
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. PMID:32532753
Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection? PMID:32532069
Digital crowdsourcing: unleashing its power in rheumatology. PMID:32527863
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. PMID:32527675
COVID-19 in rheumatic disease patients on immunosuppressive agents. PMID:32512263
COVID-19 and Its Potential Effect on Patients With Rheumatic Diseases in Latin America. PMID:32511148
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. PMID:32503857
The immune system and COVID-19: Friend or foe? PMID:32502542
Implications of COVID-19 in pediatric rheumatology. PMID:32500409
Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient. PMID:32474034
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. PMID:32471903
Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. PMID:32462761
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'. PMID:32457048
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. PMID:32425260
Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China. PMID:32425259
How to Effectively Support Patients with Rheumatic Conditions Now and Beyond COVID-19. PMID:32403182
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. PMID:32381561
Initial data from the COVID-19 Global Rheumatology Alliance provider registries - Authors' reply. PMID:32377642
Initial data from the COVID-19 Global Rheumatology Alliance provider registries. PMID:32377641
SARS-CoV-2 infection among patients with systemic autoimmune diseases. PMID:32376395 -
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry
PubMed citations: 33.
33 articles citing: Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry
Perception of risk and impact of the COVID-19 pandemic on patients with rheumatic diseases: a case-control study. PMID:35790594
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. PMID:35698725
Racial and ethnic differences in COVID-19 outcomes: a call to action. PMID:35698724
Different systemic rheumatic diseases as risk factors for COVID-19-related mortality. PMID:35499772
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4. PMID:35474640
Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review. PMID:35450954
Ethnicity-Specific Features of COVID-19 Among Arabs, Africans, South Asians, East Asians, and Caucasians in the United Arab Emirates. PMID:35368452
Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. PMID:35338032
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. PMID:35217850
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. PMID:35172961
Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. PMID:34837569
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. PMID:34778843
COVID-19 - rheumatic diseases and rheumatologists. PMID:34538938
Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. PMID:34498436
Epidemiology and Clinical Management of Rheumatic Autoimmune Diseases in the COVID-19 Pandemic: A Review. PMID:34490312
Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. PMID:34450504
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. PMID:34346564
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. PMID:34316727
Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. PMID:34189675
The impact of the COVID-19 pandemic on the field of pediatric rheumatology. PMID:34175864
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. PMID:34171857
Outcomes of COVID-19 in a cohort of pediatric patients with rheumatic diseases. PMID:34154620
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. PMID:34128356
Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. PMID:34095857
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. PMID:34049860
Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. PMID:33955209
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. PMID:33728796
The racial/ethnic and sociocultural aspects of the pandemic in rheumatology. PMID:33648855
Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. PMID:33627440
Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review. PMID:33515067
[Threat of a SARS-CoV-2 endemic in a large hospital specialized in rheumatic diseases-relative all clear through consistent testing]. PMID:33495854
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. PMID:33394601
COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. PMID:33352298 -
The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance
PubMed citations: 20.
20 articles citing: The Rheumatology Community responds to the COVID-19 pandemic: the establishment of the COVID-19 global rheumatology alliance
Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. PMID:35729973
The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey. PMID:35392427
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. PMID:35387864
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. PMID:35217850
Rapid Adoption of Telemedicine in Rheumatology Care During the COVID-19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees. PMID:34791821
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. PMID:34661663
Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. PMID:34622123
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. PMID:34171857
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. PMID:34117116
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. PMID:34049860
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. PMID:33468418
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. PMID:33394601
Association of Medication Access Difficulty and COVID-19-Related Distress With Disease Flares in Rheumatology Patients During the COVID-19 Pandemic. PMID:33278068
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. PMID:33146001
The impact of COVID-19 on rheumatology practice across Africa. PMID:33020845
#Covid4Rheum: an analytical twitter study in the time of the COVID-19 pandemic. PMID:32995894
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. PMID:32789449
Conducting research in a pandemic: The power of social media. PMID:32716838
The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis. PMID:32502509
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. PMID:32471903 -
Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey
PubMed citations: 16.
16 articles citing: Capturing Patient-Reported Outcomes During the COVID-19 Pandemic: Development of the COVID-19 Global Rheumatology Alliance Patient Experience Survey
Sociodemographic differences in patient experience with primary care during COVID-19: results from a cross-sectional survey in Ontario, Canada. PMID:35534055
Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1). PMID:35069810
A scoping review of patient engagement activities during COVID-19: More consultation, less partnership. PMID:34587175
Perceived Risk and Associated Shielding Behaviors in Patients With Rheumatoid Arthritis During the Coronavirus 2019 Pandemic. PMID:34498436
Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. PMID:34316727
Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. PMID:34047040
Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). PMID:33827969
COVID-19 and rheumatoid arthritis. PMID:33625043
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. PMID:33394601
#Covid4Rheum: an analytical twitter study in the time of the COVID-19 pandemic. PMID:32995894
Rheumatic Disease-Related Symptoms During the Height of the COVID-19 Pandemic. PMID:32982613
Rheumatologists in the COVID-19 era: will there be a new role for the rheumatologist in the care of rheumatic patients? PMID:32889590
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice. PMID:32789449
Conducting research in a pandemic: The power of social media. PMID:32716838
Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt. PMID:32710198
Implications of COVID-19 in pediatric rheumatology. PMID:32500409 -
The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice
PubMed citations: 14.
14 articles citing: The COVID-19 Global Rheumatology Alliance: evaluating the rapid design and implementation of an international registry against best practice
Risk of Severe SARS-CoV-2 Infection in Patients with Autoimmune Rheumatic Diseases in Qatar: A Cohort Matched Study. PMID:35813704
The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey. PMID:35392427
SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. PMID:35387864
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. PMID:35217850
Lupus Cohorts. PMID:34215374
Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. PMID:34171857
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. PMID:34117116
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. PMID:34049860
Myasthenia gravis and COVID-19: A case series and comparison with literature. PMID:33914898
Whom Should Be Saved? A Proposed Ethical Framework for Allocating Scarce Medical Resources to COVID-19 Patients Using Fuzzy Logic. PMID:33829020
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. PMID:33504483
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. PMID:33468418
Global research collaboration in a pandemic-challenges and opportunities: the COVID-19 Global Rheumatology Alliance. PMID:33394601
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. PMID:33146001
Tags:
Tags
More detailed information about this field from each metasource.
patient care
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
report
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Tags
More detailed information about this field from each metasource.
patient care
metasource: Fairsharing.orgversion: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
report
metasource: Fairsharing.orgversion: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
metasource: Fairsharing.org
version: FAIRsharing.org: COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance; DOI: https://doi.org/10.25504/FAIRsharing.EBhGci; Last edited: May 20, 2021, 1:44 p.m.; Last accessed: Jan 03 2022 7:06 p.m.
Need help integrating and/or managing biomedical data?